TP53 and ovarian carcinoma: Decreased LRRC8A expression reduces platinum drug uptake in p53-deficient breast cancer and ovarian cancer cells14,28 and decreases the expression and activation of p53, MDM2 (mouse double minute 2 homolog), and p21 in platinum-treated A549 lung adenocarcinoma cells, resulting in reduced platinum-induced apoptosis.38